We are live on ! Find out more
ARTL icon

Artelo Biosciences
ARTL

2 hedge funds and large institutions have $34.3K invested in Artelo Biosciences in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.04% less ownership

Funds ownership: 1.82% → 0.77% (-1%)

50% less funds holding

Funds holding: 4 → 2 (-2)

91% less capital inflows, than outflows

Capital inflows: $3.77K | Capital outflows: $44.3K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
2
Holders Change
-2
Holders Change %
-50%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$3.77K

Top Sellers

Rank Fund Capital Flow
1
HRT Financial
HRT Financial
New York
-$44K
2
UBS Group
UBS Group
Switzerland
-$164
3
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$104
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$29

ARTL Hedge Fund Activity: Q4 2023 in Review

2 of the 6,877 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q4 2023, worth a combined $34.3K — down 55% from $76.4K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ARTL and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $3.77K. The largest seller was HRT Financial, exiting entirely with an estimated $44K sold.

  • 2 institutional investors held Artelo Biosciences (ARTL) as of Q4 2023, down from 4 in Q3 2023.
  • Funds reported $34.3K of Artelo Biosciences stock for Q4 2023, down 55% quarter-over-quarter.
  • 0 funds opened new Artelo Biosciences positions in Q4 2023 and 2 closed out, a net change of -2 holders.
  • The largest Artelo Biosciences buyer in Q4 2023 was Tower Research Capital (TRC), an estimated $3.77K added.
  • The largest Artelo Biosciences seller in Q4 2023 was HRT Financial, an estimated $44K sold.

Based on aggregated 13F filings for Q4 2023.